It will be interesting to evaluate both HSPCs and lesional cells in RDD patients to assess for the presence of BRAF mutations as well as correlate the pattern of BRAF mutation involvement with clinical outcomes, especially the development of myeloid neoplasms. The gene discussed is BRAF; the disease is sinus histiocytosis with massive lymphadenopathy.